e19515 Background: To understand how novel therapies approved in relapsed multiple myeloma, e.g. carfilzomib (CFZ), are used in real-life, we describe the results of a planned interim analysis from a large observational study (NCT03091127). Methods: The study enrolled adult patients (pts) who received ≥1 prior line of therapy and ≥1 CFZ dose in routine care. Pts were followed until 30 days after last CFZ dose or up to 18 months (mos) from initiation. Results: As of 22 Oct 2018, 293 pts from 10 included EU countries were observed for a median time of 7 mos. At CFZ initiation, pts who received CFZ, lenalidomide and dexamethasone (KRd) were younger than pts treated with CFZ and dexamethasone alone (Kd): 64 vs 70 years (median), respectively. Over half of KRd pts had received 1 prior line of therapy while nearly half of Kd pts had ≥4 prior lines. Hypertension (30%), cardiac disorder (14%), diabetes (12%) and renal disorder (9%) were reported at CFZ initiation. A best response (see Table) was achieved in 3-4 mos. The total dose received relative to EU label on average was 95% and 74% by KRd (20/27 mg/m2 for K) and Kd pts (20/56 mg/m2 for K), respectively. The Kaplan-Meier median estimate of treatment duration was 16.6 mos for KRd and 7.7 mos for Kd pts. Among the 138 pts who discontinued, disease progression/refractoriness was the most frequent reason (40%). Gr3+ AEs were reported in 37% pts, including hypertension (2%) and cardiac failure (1%). Conclusions: In this real-life setting, KRd pts are younger and receive CFZ in earlier lines than Kd pts and the benefit-risk profile is consistent with published trials. The estimated treatment duration was longer than observed in other real-life data. [Table: see text]